R
ituximab, a monoclonal antibody (mAb) specific for human CD20 expressed on the surface of B-cells, has been used to treat patients with Bcell-mediated diseases such as B-cell lymphomas, immune thrombocytopenia (ITP), and other autoimmune diseases. It was recently also used to treat patients diagnosed with type 1 diabetes (1,2). Although type 1 diabetes is considered an autoimmune T-cell-mediated disease, Bcells do play a role in its development by both secreting autoantibodies specific for islet cell proteins (used as markers of the disease) and acting as antigen-presenting cell population for T-CD4 ϩ cells (3) . In fact, a recent clinical trial demonstrated the effectiveness of rituximab in the treatment of early type 1 diabetes (2).
In March 2003, a 19-year-old woman was diagnosed with ITP and started treatment with prednisone with partial response of thrombocytopenia. She required a second and third course of prednisone in July 2004 and July 2006. In December 2006, the patient began with polyuria, polydipsia, and hyperglycemia (519 mg/dl). A glycated hemoglobin level of 12.6% (HbA 1c , n.v. 4.5-6.4%) together with a decrease in C-peptide levels (0.27 pmol/ml; n.v. 0.29 -0.97) led to the diagnosis of type 1 diabetes with insulin requirements. In January 2007, she relapsed with severe thrombocytopenia. The type 1 diabetes precluded the use of prednisone, and the use of high doses of immunoglobulins did not improve the thrombocytopenia. As an alternative, she received a course of rituximab in February 2008. The platelet count returned to normal and, interestingly, insulin requirements progressively decreased until insulin was no longer needed. Eleven months after the administration of rituximab, the patient presented moderate hyperglycemia that required low doses of insulin; however, the platelet count remained normal and the B-cell count was less than 3% of the total lymphocytes even 22 months after rituximab administration.
In our patient, rituximab reversed ITP and temporally reversed hyperglycemia. There is a remarkable time coincidence between the administration of rituximab and the normalization of both platelet counts and glucose levels.
Results of a phase 2 study with rituximab in 87 newly diagnosed type 1 diabetic patients demonstrated that rituximab partially preserved ␤-cell pancreatic function for over a year (2) . In the absence of B-cells, autoreactive T-cells may continue being stimulated and infiltrating the pancreatic islets, though not accomplishing optimal pancreatic ␤-cell destruction. This likely explains why Bcell depletion was partially effective in delaying the onset of disease (4). Several studies with NOD mice have shown the importance of B-cells for the initiation of diabetes. These studies have shown that depleting B-cells with anti-CD20 mAb at different time points of the disease delayed and reduced the onset of diabetes and even reversed diabetes in over onethird of NOD mice (4,5).
In summary, we observed the normalization of the platelet counts and also a temporal normalization of type 1 diabetes parameters after the administration of rituximab in our patient diagnosed with ITP and type 1 diabetes. These findings are in agreement with recent reported studies showing the importance of B-cell collaboration in Tcell-mediated diseases. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http:// creativecommons.org/licenses/by-nc-nd/3.0/ for details.
